Radiocurability is associated with interstitial fluid pressure in human tumor xenografts

Neoplasia

Volumn 11, Issue 11, 2009, Pages 1243-1251

  Rofstad, Einar K ^a   Gaustad, Jon Vidar ^a   Brurberg, Kjetil G ^a   Mathiesen, Berit ^a   Galappathi, Kanthi ^a   Simonsen, Trude G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; BLOOD FLOW; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CELL FRACTIONATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HYPOXIC CELL; MELANOMA; MOUSE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; RADIATION DOSE; TISSUE PRESSURE; TUMOR XENOGRAFT; VASCULAR RESISTANCE;

EID: 70350704691     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91152     Document Type: Article

References (42)

1. Heldin CH, Rubin K, Pietras K, and Östman A (2004). High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4, 806-813. (Pubitemid 39331152)
2. Fukumura D and Jain RK (2007). Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101, 937-949. (Pubitemid 47040874)
3. Lunt SJ, Fyles A, Hill RP, and MilosevicM (2008). Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. Future Oncol 4, 793-802.
4. Cairns R, Papandreou I, and Denko N (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4, 61-70.
5. Boucher Y and Jain RK (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 52, 5110-5114.
6. Milosevic M, Fyles A, and Hill RP (1999). The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 43, 1111-1123. (Pubitemid 29144802)
7. Milosevic M, Fyles A, Hedley D, and Hill RP (2004). The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 14, 249-258. (Pubitemid 38903229)
8. Jain RK (1996). Delivery of molecular medicine to solid tumors. Science 271, 1079-1080.
9. Höckel M and Vaupel P (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93, 266-276. (Pubitemid 32219813)
10. Brown JM and Giaccia AJ (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
11. Rofstad EK (2000). Microenvironment-induced cancer metastasis. Int J Radiat Biol 76, 589-605.
12. Harris AL (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47. (Pubitemid 37328806)
13. Vaupel P (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14, 198-206.
14. Vaupel P and Mayer A (2007). Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26, 225-239.
15. Milosevic M, Fyles A, Hedley D, Pintilie M, Levin W, Manchul L, and Hill RP (2001). Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res 61, 6400-6405. (Pubitemid 32783245)
16. Fyles A, Milosevic M, Pintilie M, Syed A, Levin W, Manchul L, and Hill RP (2006). Long-term performance of interstitial fluid pressure and hypoxia as prognostic factors in cervix cancer. Radiother Oncol 80, 132-137. (Pubitemid 44314013)
17. Gulliksrud K, Brurberg KG, and Rofstad EK (2009). Dynamic contrast-enhanced magnetic resonance imaging of tumor interstitial fluid pressure. Radiother Oncol 91, 107-113.
18. Rofstad EK, Tunheim SH, Mathiesen B, Graff BA, Halsør EF, Nilsen K, and Galappathi K (2002). Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. Cancer Res 62, 661-664. (Pubitemid 34126937)
19. Rofstad EK (1991). Influence of cellular radiation sensitivity on local tumor control of human melanoma xenografts given fractionated radiation treatment. Cancer Res 51, 4609-4612.
20. Rofstad EK (1994). Orthotopic human melanoma xenograft model systems for studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. Br J Cancer 70, 804-812.
21. Gaustad JV, Simonsen TG, Brurberg KG, Huuse EM, and Rofstad EK (2009). Blood supply in melanoma xenografts is governed by the morphology of the supplying arteries. Neoplasia 11, 277-285.
22. Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, and Rofstad EK (2008). Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. Neoplasia 10, 354-362.
23. Brurberg KG, Graff BA, and Rofstad EK (2003). Temporal heterogeneity in oxygen tension in human melanoma xenografts. Br J Cancer 89, 350-356.
24. 2 fluctuations in human melanoma xenografts. Int J Radiat Oncol Biol Phys 58, 403-409.
25. Rofstad EK and Måseide K (1999). Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: acute and chronic hypoxia in individual tumours. Int J Radiat Biol 75, 1377-1393.
26. Hall E (2000). Radiobiology for the Radiologist. Philadelphia, PA: Lippincott Williams & Wilkins.
27. Raleigh JA, Dewhirst MW, and Thrall DE (1996). Measuring tumor hypoxia. Semin Radiat Oncol 6, 37-45.
28. Gulliksrud K, Vestvik IK, Galappathi K, Mathiesen B, and Rofstad EK (2008). Detection of hypoxic cell subpopulations in human melanoma xenografts by pimonidazole immunohistochemistry. Radiat Res 170, 638-650.
29. Rofstad EK, Galappathi K, Mathiesen B, and Ruud EBM (2007). Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis. Clin Cancer Res 13, 1971-1978. (Pubitemid 46649862)
30. Peters LJ, Brock WA, Chapman JD, and Wilson G (1998). Predictive assays of tumor radiocurability. Am J Clin Oncol 11, 275-287.
31. Rofstad EK and Måseide K (1998). Fraction of radiobiologically hypoxic cells in human melanoma xenografts measured by using single-cell survival, tumour growth delay and local tumour control as end points. Br J Cancer 78, 893-898.
32. Jain RK (1998). Determinants of tumor blood flow: a review. Cancer Res 48, 2641-2658.
33. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. Cancer Res 49, 6449-6465. (Pubitemid 20008770)
34. Bjørnæs I and Rofstad EK (2001). Microvascular permeability to macromolecules in human melanoma xenografts assessed by contrast-enhanced MRI-intertumor and intratumor heterogeneity. Magn Reson Imaging 19, 723-730. (Pubitemid 32751604)
35. Graff BA, Vangberg L, and Rofstad EK (2004). Quantitative assessment of up-take and distribution of iron oxide particles (NC 100150) in human melanoma xenografts by contrast-enhanced MRI. Magn Reson Med 51, 727-735. (Pubitemid 38420449)
36. Dewhirst MW, Cao Y, and Möller B (2008). Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8, 425-437. (Pubitemid 351744964)
37. Brurberg KG, Gaustad JV, Mollatt CS, and Rofstad EK (2008). Temporal heterogeneity in blood supply in human tumor xenografts. Neoplasia 10, 727-735.
38. Boucher Y, Lee I, and Jain RK (1995). Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 50, 175-182.
39. Tufto I, Lyng H, and Rofstad EK (1996). Interstitial fluid pressure, perfusion rate and oxygen tension in human melanoma xenografts. Br J Cancer Suppl 27, S252-S255.
40. Lunt SJ, Kalliomäki TMK, Brown A, Yang VX, Milosevic M, and Hill RP (2008). Interstitial fluid pressure, vascularity and metastasis in ectopc, orthotopic and spontaneous tumours. BMC Cancer 8, 2. (Pubitemid 351279970)
41. Heath VL and Bicknell R (2009). Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6, 395-404.
42. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.